|
|
|
Oxford Global, Le Montreux Palace, Switzerland
8th - 10th June 2010
Oxford Global Conferences is proud to present both the 11th Annual Drug Discovery Leaders Summit, which is to be held on the 9th- 10th and its Pre-Conference Symposium on Open Innovation on the 8th June 2010 at Le Montreux Palace, Switzerland. The summit is the single most senior-level and focused event in Europe dedicated to the drug discovery and pharma market. This meeting will also be co-located with Oxford Globals’s 2nd Annual GPCR Congress.
Over three days, the Summit will attract over 175 senior-level decision makers working in drug discovery from the UK, Europe and US’s leading pharmaceutical, biotech, academic and research institutions. This prestigious event provides a forum for R&D and drug discovery practitioners and prominent innovators to learn more about key solutions being provided to their industry, network with their peers, and address key industry concerns through a series of cutting edge conference presentations in a professional yet relaxed environment. In keeping with Oxford Global’s highly successful drug discovery series, an expert panel of speakers will present a full conference programme covering science, technology, strategy, data management and informatics, allowing attendees to gain an essential industry update. The symposium will be chaired by Thomas Senderovitz, Senior Vice President Global Development, Grunenthal. Key topics include: OPEN INNOVATION SYMPOSIUM – 8th June 2010
Defining Open Innovation, Business Models, IP and Collaboration Issues, Academia Open Innovation, Biopharma Open Innovation, Current Open Innovation Initiative and Case Studies
DRUG DISCOVERY SUMMIT – 9th-10th June 2010
R&D STRATEGIES & BUSINESS MODELS AND PHARMA/BIOTECH ALLIANCES COLLABORATIONS –Challenges and strategies to enhance productivity in drug discovery such as open innovation, innovative business models, lean thinking and the benefits of industry and academic alliances
MEDICINAL CHEMISTRY / DRUG DESIGN – Reducing attrition in development, fragment based techniques, flow chemistry, reducing risk of toxicity, structure based discovery as well as hit to lead strategies
SCREENING TECHNIQUES & ASSAY DEVELOPMENT – Improving quality of assays, compound selection, target selection and validation, as well as cost effective lead identification Initiatives for HTS, HCS and label free as well as the potential of pluripotent stem cells
BIOMARKERS & PERSONALISED / TRANSLATIONAL MEDICINE –Translational medicine and diagnostic case studies as well as how Biomarkers facilitate early decision making in early development
BIOINFORMATICS – In-silico data, predictive modelling, Systems Biology
BIOLOGICS – Strategies to integrate biologics into an organisation, including presentations in phage display in peptides, a panel discussion on biobetters, case study on pepducins WHO ATTENDS?
Delegates are pre-qualified dependent on budget, responsibility and seniority. Delegates are senior-level decision makers, from major pharmaceutical and biotech companies based in Europe and typically include SVPs, VPs and Directors of: Drug Discovery Biomarkers Medicinal Chemistry Screening Strategic Alliances R&D Screening Enabling Technologies Genomics Enabling Science Toxicology Proteomics Structural Biology Bioinformatics Assay Development Systems Biology Translational Medicine Lead Generation/ Validation/ Optimisation Biologics Open Innovation Technology Transfer External Research Business Strategy Technology Scouting Business Development Strategic Alliances Strategy & Planning
YOUR NETWORKING OPPORTUNITIES
Meet face-to-face with leading solution providers and senior-level industry peers through a series of formal and informal networking opportunities. Using our online appointment system, you are able to view the full profiles of all solution provides before the event. In addition you have the chance to pre-arrange one-to-one meetings with them, giving you the opportunity to discuss technologies, services and solutions that address your key business needs. Categories of solution providers include: Biomarkers Imaging Strategy & Planning Pre Clinical Analytical Testing HTS / HCS RNAi Protein Sequencing Microarray Technology Protemics Genomics Emerging Technologies Data Management
|
|
|
|
|
|
Organized by:
|
|
Oxford Global |
|
Invited Speakers:
|
|
• Andrew von Eschenbach, Senior Advisor, Greenleaf Health • Michel Pairet, Corporate Senior Vice President, Research, Boehringer Ingelheim • Ian Tomlinson, Senior Vice President, Biopharmaceuticals R&D, GlaxoSmithKline • Stephen Friend, President, CEO and a Co-Founder, Sage Bionetworks • Claude Bertrand, Executive Vice President & Chief Scientific Officer, Ipsen • Nick Terrett, Chief Scientific Officer, Ensemble Discovery Corporation • Søren Bregenholt, COO, Symphogen • Rob Hayes, CSO, CENTYREX a J&J Internal Venture • Steve Hunt III, Senior Vice President, Discovery Research, Ascent Therapeutics • John Desjarlais, Vice President, Research, Xencor • Andrew Hopkins, Research Professor of Translational Biology & Chair of Medicinal Informatics Division of Biological Chemistry and Drug Discovery College of Life Sciences University of Dundee • Jeremy Everett, Vice President, Research Centres of Emphasis, Sandwich, Pfizer • Ben Askew, Vice President Research, Head of NCE Technologies, EMD Serono Research Institute • Jutta Heim, Chief Technology Officer, Evolva SA • Orest Hurko, Assistant Vice President Discovery Translational Research, Pfizer • Marc Pfister, Executive Director, Discovery Medicine, and Clinical Pharmacology, Head of Strategic Modeling and Simulation, Bristol Myers Squibb • Karyn O'Neil , CSO, Johnson & Johnson Ventures • Anne Phelan, Executive Director Research Enabling Group, Pfizer • Salvatore Alesci, Senior Director & Head, Translational Immunology, Pfizer • John Overington, Team Leader, Chemogenomics, EMBL – European Bioinformatics Institute, EMBL-EBI • Mark Bunnage, Executive Director, Medicinal Chemistry, Pfizer • Craig Johnstone, Value Chain Leader, RA-CVGI, AstraZeneca • Jay P. Siegel, Chief Biotechnology Officer, Johnson & Johnson • Marjoleen Nijsen, Head Preclinical PK/PD, Abbott GmbH & Co. KG, Germany • Steven Ley, BP 1702 Professor of Organic Chemistry, Innovative Technology Centre, Department of Chemistry, Cambridge University • Birgit Schoeberl, Vice President of Discovery, Merrimack Pharmaceuticals • Paul Wyatt, Director of Drug Discovery, Division of Biological Chemistry & Drug Discovery, College of Life Sciences, University of Dundee • Jin Li, Director of Computational Chemistry, AstraZeneca • Jürgen Moll, Director, Dep. Cell Biology, Oncology, Nerviano Medical Sciences • David J. Heard, Group Head Bioinformatics in Investigative Toxicology, Preclinical Safety, Novartis Institutes for Biomedical Research • John Burke, Associate Director, Systems Biology, Biotherapeutics and Integrative Biology, Boehringer Ingelheim Pharmaceuticals • Michael Braxenthaler, External Liaison Officer, The Pistoia Alliance & Global Head Strategic Partnerships and Sourcing Pharma Research Scientific Informatics (PRI) F. Hoffmann-La Roche Inc • Niklas Blomberg, Associate Director, Computational Chemistry, AstraZeneca • Jeffrey Waring, Associate Research Fellow, Senior Group Leader, Neuroscience Biomarker Discovery, Abbott • Didier Pez, Team Leader Medicinal Chemistry, AB Science • Ge Li, Chairman and CEO, WuxiApptec • Alastair Lawson, Senior Director of Structural Biology, UCB • Didier Pez, Team Leader Medicinal Chemistry, AB Science • Jean-François Mayaux, Global Leader, Biotherapeutics & Protein Sciences, Sanofi Aventis • Andy Davis, Associate Director, Physical & Metabolic Sciences, AstraZeneca • Hans Winkler, Senior Director, Global Head Oncology Biomarkers, Ortho Biotech - Johnson & Johnson • Anthony Davies, HCA Research Facility Manager, Trinity College Dublin • Troels Koch, Vice President & CTO, Santaris Pharma A/S • Andrea Cavalli, Senior Scientist, Computational Chemistry, Department of Drug Discovery and Development, Italian Institute of Technology, Genoa • Maria Miteva, Senior Scientist, Molécules Thérapeutiques in silico (MTi) Université Paris • Senior Représentative Accelrys
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
Registration:
|
|
Academic £450, Industry £650, Vendor £1250. Poster presentations £125. Limited time discounts may be available for more information contact us at d.morris@oxfordglobal.co.uk or +44 (0)1865 304925
|
|
E-mail:
|
|
d.morris@oxfordglobal.co.uk
|
|
|
|
|
|
|
|